Featured Research

from universities, journals, and other organizations

Common cholesterol drug safe, may improve learning disabilities in patients with neurofibromatosis, study finds

Date:
September 27, 2011
Source:
Children's National Medical Center
Summary:
Researchers have found that a cholesterol-lowering statin drug appears to be safe in children with neurofibromatosis type 1 (NF1) and may improve learning disabilities, including verbal and nonverbal memory.

Researchers at Children's National Medical Center have found that a cholesterol-lowering statin drug appears to be safe in children with neurofibromatosis type 1 (NF1) and may improve learning disabilities, including verbal and nonverbal memory. This is the first time that the drug lovastatin has been studied in children with NF1.

Related Articles


The study, led by Maria T. Acosta, MD, a pediatric neurologist and researcher at Children's National and clinical director and cognitive director of the Gilbert Family Neurofibromatosis Institute, appears in the October 2011 issue of Pediatric Neurology.

Lovastatin is currently approved by the U.S. Food and Drug Administration in adults and children for the treatment of high cholesterol. The drug works by inhibiting a specific enzyme in cholesterol biosynthesis. Previous animal studies have found that lovastatin affects a related molecular pathway that may be linked to cognitive deficits in neurofibromatosis.

"While we originally set out to determine the safety of lovastatin in NF1 patients, we also saw statistical improvements in memory and visual attention, which is a big step towards helping improve our patients' quality of life and in evaluating biologic agents which may be effective therapies for NF1," stated Dr. Acosta. "While this is a relatively small study, we now have strong baseline information, and we are working with other institutions in the country and throughout the world to perform a definitive study to replicate these findings on a larger scale."

This Phase I study looked at the safety and efficacy of lovastatin as a treatment for patients with neurofibromatosis type 1, which accounts for the majority of NF cases. Over a period of three months, 24 patients between ages 10-17 years received treatment with lovastatin. Patients were given cognitive functioning tests before and after treatment. All patients maintained normal cholesterol levels throughout the study, and there were some cognitive improvements in memory, visual attention, and efficiency following treatment.

"The implications for all children with learning disabilities -- not only those with NF1 -- are of interest to the greater pediatric community, so we hope to move forward quickly through the Consortium to advance this research in NF1 patients in a timely manner," commented Roger Packer, MD, Senior Vice President of the Center for Neuroscience and Behavioral Medicine, Director of the Gilbert Family Neurofibromatosis Institute at Children's National, and Group Chair of the Department of Defense Neurofibromatosis Clinical Trials Consortium.

The Gilbert Family Neurofibromatosis Institute at Children's National is one of the largest institutes in the world and is an international leader in the treatment of neurofibromatosis, a genetic disorder that has an incidence rate of 1 in 3,000 births. Of those affected by neurofibromatosis type 1, upwards of 90 percent of those cases show deficits in motor skills and learning disabilities. NF1 is also associated with an increased incidence of brain tumors and damaging and often disfiguring neurofibromas.


Story Source:

The above story is based on materials provided by Children's National Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Maria T. Acosta, Peter G. Kardel, Karin S. Walsh, Kenneth N. Rosenbaum, Gerard A. Gioia, Roger J. Packer. Lovastatin as Treatment for Neurocognitive Deficits in Neurofibromatosis Type 1: Phase I Study. Pediatric Neurology, 2011; 45 (4): 241 DOI: 10.1016/j.pediatrneurol.2011.06.016

Cite This Page:

Children's National Medical Center. "Common cholesterol drug safe, may improve learning disabilities in patients with neurofibromatosis, study finds." ScienceDaily. ScienceDaily, 27 September 2011. <www.sciencedaily.com/releases/2011/09/110927124701.htm>.
Children's National Medical Center. (2011, September 27). Common cholesterol drug safe, may improve learning disabilities in patients with neurofibromatosis, study finds. ScienceDaily. Retrieved January 29, 2015 from www.sciencedaily.com/releases/2011/09/110927124701.htm
Children's National Medical Center. "Common cholesterol drug safe, may improve learning disabilities in patients with neurofibromatosis, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/09/110927124701.htm (accessed January 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, January 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Oxfam Calls for Massive Aid for Ebola-Hit West Africa

Oxfam Calls for Massive Aid for Ebola-Hit West Africa

AFP (Jan. 29, 2015) Oxfam International has called for a multi-million dollar post-Ebola "Marshall Plan", with financial support given by wealthy countries, to help Guinea, Sierra Leone and Liberia to recover. Duration: 01:10 Video provided by AFP
Powered by NewsLook.com
Are We Winning The Fight Against Ebola?

Are We Winning The Fight Against Ebola?

Newsy (Jan. 29, 2015) The World Health Organization announced the fight against Ebola has entered its second phase as the number of cases per week has steadily dropped. Video provided by Newsy
Powered by NewsLook.com
Calif. Health Officials Campaign Against E-Cigarettes

Calif. Health Officials Campaign Against E-Cigarettes

Newsy (Jan. 29, 2015) The California Health Department says e-cigarettes are a public health risk for both smokers and those who inhale e-cig smoke secondhand. Video provided by Newsy
Powered by NewsLook.com
Measles Scare Sends 66 Calif. Students Home

Measles Scare Sends 66 Calif. Students Home

AP (Jan. 29, 2015) Officials say 66 students at a Southern California high school have been told to stay home through the end of next week because they may have been exposed to measles and are not vaccinated. (Jan. 29) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins